Fig. 2. A representative cases of durable activity of ¹⁷⁷Lu-PSMA-617.

Seventy-one-year-old mCRPC patient with nodal and lung metastases and circulating AR normal, previously treated with docetaxel, abiraterone, and cabazitaxel. The patient received 4 cycles of 177Lu-PSMA-617 radioligand therapy (activity per cycle: 4.4 GBq every 6–8 weeks). October 2017, baseline PSA = 52.4 ng/mL; May 2018 post-¹⁷⁷Lu-PSMA therapy PSA: 2.26 ng/mL. October 2018 disease relapse (nodes, lung, and bone). a Pre-therapy PSMA-PET/CT, b baseline ¹⁷⁷Lu PSMA whole-body scan, c post-therapy ¹⁷⁷Lu PSMA whole-body scan, d post-therapy PSMA-PET/CT, e PSMA-PET/CT at last follow-up.